ERS Genomics Licenses CRISPR Gene Editing Technology to Bioneer to Further Advance Preclinical Disease Modelling
Product News Jun 10, 2019
ERS Genomics Limited and Bioneer A/S today announced the signing of a license agreement providing Bioneer access to CRISPR/Cas9 genome editing technology intellectual property. Bioneer, a Denmark based life science research and technology provider, will utilize CRISPR/Cas9 technology to generate a range of innovative human cell based disease models.
Under the terms of the license, Bioneer is able to generate and commercialize CRISPR-edited cell based models, broadening its core capabilities and expanding on Bioneer's expertise in biomedical research support.
Eric Rhodes, CEO of ERS Genomics, said: “Bioneer has proven expertise in a broad array of biomedical fields. Adding CRISPR/Cas9 to their toolbox ensures they remain on the leading edge of technology. We are very pleased that Bioneer chose to expand on its service offering by licensing CRISPR/Cas9 technology through ERS Genomics."
“This cutting-edge technology will complement Bioneer’s competences in advanced preclinical disease modelling.” stated Lars H. Pedersen, CEO of Bioneer. Christian Clausen, CSO of Bioneer continues: “Bioneer is working with both industry and academia to solve complex disease relevant questions by using advanced disease modelling. The CRISPR/Cas9 tools will enable clients and collaborators to precisely tailor their preclinical modelling strategies to their specific needs for predictive in vitro models.”